Spectinomycin HCl is also used in human medicine as a reserve antibiotic API, supplied for the manufacture of injectable formulations in settings where first-line options are unsuitable. It remains one of the safest aminoglycosides for injectable administration in penicillin-allergic patients.
| CAS Number | 22189-32-8 |
|---|---|
| Molecular Formula | C14H24N2O7 · 2HCl · 5H2O |
| Molecular Weight | 495.35 |
| Pharmacopoeia | USP/IN HOUSE/EP |
| Packaging | 25 KG/DRUM |
Spectinomycin Hydrochloride (Pharma Grade) is an aminoglycoside antibiotic produced by Streptomyces spectabilis, first discovered by Mason et al. in 1961. It demonstrates high antibacterial activity against Neisseria gonorrhoeae (including β-lactamase producing strains) and moderate activity against many Enterobacteriaceae species. It also shows good activity against Ureaplasma urealyticum.
In human medicine, Spectinomycin HCl serves as an important alternative therapy for penicillin-allergic patients. It is supplied as a reserve antibiotic API for injectable formulations. Its oral absorption is superior to other aminoglycosides such as neomycin sulphate, kanamycin sulphate, and gentamicin sulphate. It is also the safest aminoglycoside for injectable administration.
| Purity | As per USP/EP monograph |
|---|---|
| Residual Solvents | Compliant with ICH Q3C |
| Heavy Metals | Compliant with pharmacopoeia limits |
| GMP Status | Manufactured under GMP conditions |
First-line intramuscular therapy for uncomplicated gonococcal infections, particularly in penicillin-allergic patients and β-lactamase-producing strains.
Used in combination regimens for pelvic inflammatory disease (PID) as an alternative to cephalosporin-based therapy.